Torrent Pharma (TORRENTPH) is an Ahmedabad-based flagship company of the Torrent group. TORRENTPH manufactures bulk drugs and formulations in the therapeutic areas of cardiovascular and central nervous system and has achieved presence in gastro-intestinal, diabetology, anti-infective and pain management segments. Domestic formulations generate more than 60% of the revenues. TORRENTPH has six marketing divisions, each catering to defined therapeutic segment. TORRENTPH has launched 22 new formulations in the domestic market and developed 14 formulations for Europe, Russia and Brazil. It has set up a subsidiary in Brazil, strengthened its focus on Russia and CIS countries during 2004-2005 .
The company commenced exports of Lamotrigine to the EU market. TORRENTPH`s sister concern, Torrent Gujarat Biotech was established in 1992 for producing Penicillin through fermentation technology developed by the Torrent group. TORRENTPH, with an R&D expenditure of Rs 673.2 million (14.3% of turnover) has set up an R&D center engaged in the discovery of new chemical entities for vascular complications and metabolic disorders. The company has taken up a project in collaboration with AstraZeneca. The company is also subject to DPCO (drug price control order - currently applicable to 24 drugs) under which there are three tiers of regulations - on bulk drugs, on formulations and on overall profitability.
The company commenced exports of Lamotrigine to the EU market. TORRENTPH`s sister concern, Torrent Gujarat Biotech was established in 1992 for producing Penicillin through fermentation technology developed by the Torrent group. TORRENTPH, with an R&D expenditure of Rs 673.2 million (14.3% of turnover) has set up an R&D center engaged in the discovery of new chemical entities for vascular complications and metabolic disorders. The company has taken up a project in collaboration with AstraZeneca. The company is also subject to DPCO (drug price control order - currently applicable to 24 drugs) under which there are three tiers of regulations - on bulk drugs, on formulations and on overall profitability.
